Kornimate/medical-research-clean huggingface dataset:
personalized mean arterial pressure management on renal function during septic shock

Conditions: Septic Shock; Acute Kidney Injury

Summary: sepsis is the most severe complication of infections. sepsis-associated acute kidney injury (aki) is commonly encountered in critically ill patients and independently predicts poor outcome. unfortunately, no drug or management strategy was able to reduce incidence of aki. to adapt the level of mean arterial pressure according to local renal hemodynamic evaluated by renal doppler could lead to a better renal perfusion, and then less aki.

acute kidney injury (aki) is a frequent and serious complication of sepsis. renal ischemia plays a major role in the pathophysiology of sepsis-associated aki. there is currently no treatment to prevent or to treat aki. it has been shown that a resistivity index (ri) greater than 0.74 of patients with septic shock could predict the occurrence of renal failure, and that increase mean arterial pressure (map) with norepinephrine could decrease ri. hence, we propose to compare the frequency and the severity of the sepsis-associated aki according to the early hemodynamic management of septic shock. patients will be randomized in a classic group (map 65 mmhg) and an interventional group (map 85 mmhg). we can thus determine whether the level of map influences renal function, and whether this influence of map is dependent of renal perfusion assessed by renal doppler. participants will be followed for the duration of hospital stay, an expected average of 4 weeks. primary endpoint: -presence and severity of sepsis-associated aki at day 7. secondary endpoints: * acute renal failure measured by classification aki at day 28. * acute renal failure as measured by the rifle classification in the fourth to seventh day and 28th day. * use of renal replacement therapy during hospitalization in intensive care unit * mortality at day 28 duration of study: recruitment: 10 months, the patient monitoring: 28 days ± 3 days, total test duration: 11 months

Eligibility criteria:
inclusion criteria: * any patient with septic shock may be included in the next 6 to 16h * age \> 18 years old and \<= 80 years exclusion criteria: * chronic renal failure (baseline serum creatinine \> 120 mmol/l) * chronic cardiac failure (left ventricle ejection fraction \< 40%) * pregnancy * urinary tract infection * patients with a left ventricular dysfunction ( ventricular ejection fraction \<40%)

Keywords: sepsis acute kidney injury mean arterial pressure catecholamines renal doppler
a retrospective study investigating the factors related to non-tuberculous mycobacterial pulmonary disease in hong kong

Conditions: Non-Tuberculous Mycobacterial Pneumonia

Summary: in this retrospective study, we aim to investigate the demographic and clinical features of patients with nontuberculous mycobacteria (ntm) lung disease in our hospital and the trends and diversity of ntm species isolated in the period of 2009-2018.


Eligibility criteria:
inclusion criteria: * patients older than 18 years old. * patients with one or more respiratory isolates (namely, sputum, tracheal aspirates, bronchial washing, bronchial aspirates, bronchial trap and bronchoalveolar lavage) of mycobacteria collected in the prince of wales hospital in the period of 2009-2018. exclusion criteria: * none
evaluation of the switch from the original infliximab to its biosimilar in daily practice at cochin hospital

Conditions: Rheumatoid Arthritis; Spondyloarthritis; Crohn's Disease; Uveitis

Summary: the purpose of this study is to evaluate the effectiveness of the switch from the original infliximab ( remicade®) to its biosimilar (inflectra®) in all the patients at cochin hospital receiving remicade® for either a rheumatic, gastro-enterologic or ophthalmic condition

all patients managed in one of the departments of cochin hospital who are receiving the original infliximab ( remicade®) from at least 4 months will be invited to continue to receive infliximab but using its biosimilar (inflectra®)) at the same regimen (identical dose per infusion and interval between two infusions) than the previous one while receiving remicade®. the tolerability of the infusion will be recorded as well as the percentage of patients continuing inflectra® after at least six months of its initiation. moreover, the infliximab serum level will be evaluated after the last infusion of remicade® and after the third infusion of inflectra®. at the same time, anti-drug antibodies will be tested. finally for each of the underlying disease (e.g. rheumatoid arthritis, spondyloarthritis, crohn's disease, uveitis,..), the maintenance of the efficacy of infliximab will be evaluated according to the usual outcome measures of the activity of the disease

Eligibility criteria:
inclusion criteria: * male or female over 18 year old * patient treated with remicade® in cochin hospital * more than 3 perfusions of remicade® before the switch to inflectra® exclusion criteria: * none

Keywords: biosimilar
bcaas in concussion 2.0

Conditions: Concussion, Brain; Concussion, Mild; Concussion

Summary: this study is a randomized, placebo-controlled, double-blinded, therapeutic exploratory clinical trial of branched chain amino acids (bcaas) in the treatment of concussion. the aim of the study is to determine whether administration of high-dose bcaas compared to placebo promotes concussion recovery.

annually, approximately 2 million concussions occur in the pediatric and young adult population. approximately 30% of those diagnosed with concussion will experience persisting symptoms lasting beyond 28 days. concussion is a heterogeneous injury to the brain that precipitates a complex pathophysiological process that can result in a cascade of deleterious side effects. at present, there are no targeted therapeutics that can mitigate or prevent the deleterious effects of concussion. in preclinical, analysis of ipsilateral hippocampi isolated from mice after traumatic brain injury (tbi) demonstrated that only the concentrations of the three branched chain amino acids (bcaas) (valine, isoleucine, and leucine) were significantly reduced after injury. when these brain-injured animals received dietary supplementation with bcaas, the concentrations of these amino acids were restored in the injured hippocampus and the injured animals demonstrated significant cognitive improvement to levels comparable to those obtained in non-injured control animals. the pilot study (nct01860404) provides evidence of bcaas in concussed adolescents and young adults providing a dose-response effect in reducing concussion symptoms and a return to baseline physical activity in those treated with higher total doses of bcaas, warranting this larger trial to inform clinical practice around bcaa treatment in concussion.

Eligibility criteria:
inclusion criteria: 1. males and females,11 - 23 years of age. 2. weigh at least 40kg. 3. meeting concussion criteria for the american congress of rehabilitative medicine. 4. present within 4 days of injury. 5. post-menarchal females must have a negative urine pregnancy test and must use an acceptable method of contraception. 6. informed consent by the participant, or for participants \<18 years old both informed consent by a parent/guardian and child assent. exclusion criteria: 1. evidence of moderate or severe traumatic brain injury (tbi), including glasgow coma scale (gcs) \<13, tbi requiring hospital admission, or tbi requiring neurosurgical intervention. 2. prior concussion or tbi within 90 days. 3. known history of maple syrup urine disease or known family history of maple syrup urine disease. 4. any investigational drug use within 30 days prior to enrollment. 5. hypersensitivity to any ingredient in the active or placebo products. 6. participants who are pregnant, planning on becoming pregnant during the study duration, or breastfeeding. 7. non-english speaking participants or parent/guardian.
the relationship between posture, sense of position, musculoskeletal discomfort and anxiety

Conditions: Kyphosis Postural Thoracic; Proprioception; Musculoskeletal System; Anxiety

Summary: it is known that posture is affected by various factors such as somatosensation, visual perception and cognition. in addition, it is also thought to affect conditions such as stress and anxiety through receptors. the aim of this study was to investigate the relationship between postural changes such as thoracic kyphosis, musculoskeletal problems, trunk position sense and anxiety in young individuals who were asymptomatic in terms of musculoskeletal problems.


Eligibility criteria:
inclusion criteria: * 18 years and older * volunteered to participate in the study * no systemic or neurological disease exclusion criteria: * severe visual and hearing problems * orthopedic injury or surgery in the last 6 months
pet/ct vs bone marrow biopsy in exclusion of bone marrow infiltration for initial staging of lymphoma

Conditions: Lymphoma

Summary: lymphoma is a common malignancy in the developed world. the two main categories of lymphoma are non-hodgkin lymphoma and non-hodgkin lymphoma. bone marrow biopsy (bmb) is the most direct method of detecting lymphoma infiltration, however it is an invasive procedure. 18 fluro-2deoxy-d glucose pet/ct is a non-invasive examination that can comperhensively evaluate the state of bone marrow (bm) with extremely high sensitivity in detecting bone marrow infiltration of lymphoma.

lymphoma is a common malignancy in the developed world. many subtypes of lymphomas are known. the two main categories of lymphoma are the non-hodgkin lymphoma (nhl) (90% of cases) and hodgkin lymphoma (hl) (10%). lymphoma makes up 3-4% of all cancers, making them as a group the seventh-most common form. bone marrow biopsy is the most direct method of detecting lymphoma infiltration, however, it is an invasive procedure which is accompanied by several complications such as pain, hemorrhage and may miss marrow involvement if infiltration is patchy, or not taken from a part of the marrow that is involved. 18fluoro-2-deoxy-d-glucose (fdg) positron emission tomography/computed tomography (pet/ct) is a non-invasive examination that can comprehensively evaluate the state of bone marrow with extremely high sensitivity in detecting bone marrow infiltration of lymphoma and can replace bone marrow biopsy. at this moment, there is no clear international guideline between the indications of pet-ct and bone marrow biopsy, but there is interest in using the pet/ct findings to either supplement or even replace the bmb in the evaluation of bm involvement in lymphoma.

Eligibility criteria:
inclusion criteria: * initial diagnosed patient not receiving treatment. * baseline bone marrow biopsy. * baseline pet/ct. * the period between performing pet/ct and bone marrow biopsy is maximum 30 days and without lymphoma treatment between the studies. exclusion criteria: * patient receiving chemotherapy or corticosteroid before doing pet/ct and bmb. * patients with known concomitant malignancy. * patients who received hemopoietic growth factor injections less than 48 hours before the pet/ct. * patients with previously known and treated lymphoma.

Keywords: lymphoma pet/ct bone marrow
clinical trial to evaluate the efficacy and safety of ckd-386

Conditions: Dyslipidemia Patients With Hypertension

Summary: clinical trial to evaluate the efficacy and safety of ckd-386


Eligibility criteria:
inclusion criteria: 1. subjects are diagnosed with dyslipidemia patients with hypertension or are being administered anti-hypertension and anti-hypertension drugs after diagnosis. 2. subjects who agreed to participate in this clinical trial voluntarily. exclusion criteria: 1. subjects who were satisfied specific blood pressure levels that measured at screening period. 2. subjects who were satisfied specific lipid levels that measured at screening period. 3. subjects who cannot participate in a clinical trial based on the pi's judgment.
treatment for depressed preadolescent girls

Conditions: Depression

Summary: this study will compare the effectiveness of three therapies for the treatment of depression in preadolescent girls.

depressive disorders during childhood are virulent, long-lasting disorders that are a risk factor for the development of future depressive episodes and other psychiatric difficulties. a dysfunctional family environment is a possible pathway to the development of depression in adolescents. the family environment is an especially salient context for the development of depression in preadolescent girls. depression is expressed differently between male and female adolescents; girls may not benefit as much as boys from treatments such as cognitive behavioral therapy (cbt) because the treatments may not target disturbances and skills that are specific to preadolescent girls. this study will identify effective treatments for depression in preadolescent girls. depressed participants are randomly assigned to receive cbt, cbt plus parent training (pt), or a minimal contact control (mcc). the cbt group receives treatment twice a week for 10 weeks. participants in the cbt plus pt group receive therapy sessions and group treatment for 10 weeks. participants in the mcc group meet with a research associate once a week for 10 weeks. during the control visits, the child's depressive symptoms are assessed, but no advice or treatment is given. participants are assessed at baseline, post-treatment, and at yearly follow-up visits for up to 4 years. school performance, home environment, and the impact of the interventions on parent adjustment are evaluated.

Eligibility criteria:
inclusion criteria: * depressive disorder exclusion criteria: * learning disability or limited intellectual ability * health-related illness that would prevent the patient from completing the research study
study of the prevalence of osteo-metabolic complications in patients with thyroid cancer

Conditions: Cancer of Thyroid; Vertebral Fracture; Osteoporosis

Summary: this is a multicenter retrospective observational study aimed to evaluate the prevalence of osteo-metabolic complications in patients with thyroid cancer.

approximately 150-200 outpatients evaluated in the endocrinology unit of the irccs san raffaele hospital and the nuclear medicine unit of the spedali civili of brescia will be included in the study. during the follow-up visits, patients who meet the inclusion criteria will be offered inclusion in the study. after signing the informed consent, the patient's anamnestic and clinical (biochemical, radiological, anamnestic) data will be retrospectively collected in an electronic database. sensitive data will be anonymized.

Eligibility criteria:
inclusion criteria: * age ≥ 18 years * histological diagnosis of thyroid carcinoma * radiological data from chest x-ray in lateral projection in the preoperative evaluation on which the vertebral morphometry * signing of the informed consent exclusion criteria: * subjects not falling within the previously described criteria are excluded
ongoing registry of treatment of venous thromboembolism

Conditions: Deep Vein Thrombosis; Thromboses, Venous; Thrombosis Embolism; Postthrombotic Syndrome; Pulmonary Embolism

Summary: ongoing registration of patients with venous thromboembolism treated by means of antithrombotic therapy, thrombolisys, open surgery, endovenous desobstruction and stenting.

data of patients with vte treated in different russian medical centers are entered in a prospective digital database, and continuously updated. there is planned to conduct prospective randomized, cohort and observational studies on the site of register

Eligibility criteria:
inclusion criteria: * case of venous thrombosis of a limb or pulmonary embolus exclusion criteria: * no exclusion criteria
study to evaluate pharmacokinetics of itca 650 in subjects with renal impairment compared to normal subjects

Conditions: Renal Insufficiency

Summary: a phase 1 study to evaluate the pharmacokinetics of itca 650 in subjects with mild and moderate renal impairment compared to the pharmacokinetics of subjects with normal renal function


Eligibility criteria:
inclusion criteria: * body mass index between 22 and 40 kg/m² * subjects meeting pre-defined estimated glomerular filtration rate criteria and creatinine clearance rate * normal (≥90 ml/min/1.73 m2) * mild (60-89 ml/min/1.73 m2) * moderate (45-59 ml/min/1.73 m2) * moderate (\>30-44 ml/min/1.73 m2) exclusion criteria: * history of acute metabolic complications * uncontrolled hypertension * history of hypersensitivity to exenatide * cardiovascular disease * history of acute or chronic pancreatitis * personal or family history of multiple endocrine neoplasia type 2 * history of medullary thyroid cancer * severe renal failure, end stage renal disease or dialysis
3 months versus 12 months dual antiplatelet therapy after drug-eluting stent implantation in stemi

Conditions: ST Elevation Myocardial Infarction

Summary: to compare the clinical outcomes of dual antiplatelet therapy with aspirin and p2y12 receptor inhibitor vs. ticagrelor monotherapy at 3 months after pci in patients with st-elevation myocardial infarction.

the purpose of this study is to compare the use of ticagrelor alone versus p2y12 receptor inhibitor and aspirin together after pci among st-elevation myocardial infarction patients who complete 3-month course of dual antiplatelet therapy. the object of this study is to determine the effectiveness and safety of ticagrelor alone, compared to p2y12 receptor inhibitor plus aspirin in reducing clinically relevant bleeding and in reducing ischemic adverse events among patients diagnosed with st-elevation myocardial infarction undergoing pci with second-generation drug-eluting stent.

Eligibility criteria:
inclusion criteria: * patients ≥ 19 years old * patients who received new generation sirolimus-eluting (osiro®) stent implantation for treating acs * provision of informed consent exclusion criteria: * age \> 80 years * pregnant women or women with potential childbearing * life expectancy \< 1 year
neuroleptic and huntington disease comparison of : olanzapine, la tetrabenazine and tiapride

Conditions: Huntington Disease

Summary: huntington's disease (hd) is autosomal dominant neurodegenerative disease, starting in average (with high variability) in the fourth decade. the disease progression is classically characterized by a cognitive deterioration (cortical-frontal dementia), motor disorders (associating chorea, dystonia and bradykinesia), psychiatric disturbances (combining depression and irritability) and metabolic disorder (cachexia). the disease is fatal within 15 to 20 years in most patients. hd has no cure. neuroleptics are the main drug used and the only to demonstrate its efficacy on chorea in clinical trials. but neuroleptics have also beneficial and adverse effects on other disease characteristics (motor, psychiatric, cognitive or metabolic). their profile between beneficial and adverse effects could be different according the neuroleptics and their classification. the aim of this study is to compare beneficial and adverse effects of 3 different neuroleptics in hd.

we proposed a randomized controlled trial, including 180 patients, in 3 groups: olanzapine, tetrabenazine and tiapride, followed during 12 months. these treatments have been selected according their profile and their frequency of use. the principal criteria is the independence scale, one of the functional scales of the unified huntington's disease rating scale, the only validated scale in hd. secondary criteria will assess motor,functional, psychiatric and cognitive functions, metabolic parameters, tolerance and cost.

Eligibility criteria:
inclusion criteria: 1. symptomatic disease with motor, behavioural and/or psychiatric disorder required medical treatment. 2. hd diagnosed with abnormal number of cag repeats: 38 ≤ nucleotide expansion (cag) (amendment n°5 suppressed the limit ≤ 48) 3. neuroleptic prescription required. 4. age ≥ 18 (amendment n°5 suppressed the limit ≤ 65 years old) 5. patient gave its written consent 6. realization of medical examination and a electroencephalogram exclusion criteria: 1. severe cognitive impairment or neuropsychiatric troubles. 2. existing diabetes. 3. neuroleptic prescription forbidden according to the neurologist decision. 4. current participation to another clinical trial. 5. no drug compliance to previous treatment. 6. no national health insurance affiliation

Keywords: huntington neuroleptic unified huntington disease rating scale (uhdrs) independence scale neuroleptic prescription required
misp 60528 pneumococcal vaccination

Conditions: Heart Transplant Infection Prevention

Summary: this study aims to use two different blood tests (elisa and opa) to study response to pneumococcal vaccination administered as per standard guidelines in patients who are undergoing workup for heart transplant (whether or not they have undergone lvad implantation or have undergone heart transplant.

the patients will be receiving vaccination consistent with standard of care guidelines, regardless of study participation. the additional risk of study participation would be the risks associated with venipuncture (injury to vessel or nerve, syncope). patients will not accrue benefits personally. however, participation will help others by identifying whether current vaccination strategies in this population are adequate.

Eligibility criteria:
inclusion criteria: * age 18 or over * either undergoing evaluation for heart transplant (with or without lvad receipt), or having received a heart transplant * receiving a dose of pcv15 or ppsv23 (or both sequentially) concordant with ast guidelines exclusion criteria: * infants and children under age 18 * subjects without the capacity to consent * pregnancy * already up to date on pneumococcal vaccination or declining vaccination
circulating micro rnas expression in egyptian bronchial asthma and copd patients

Conditions: Asthma; COPD

Summary: this cross sectional study will be carried out on 30 subjects who will be recruited from the outpatient clinic of chest department, tanta university hospital. they will be classified into 3 groups: group i: it will include 10 healthy volunteer subjects. group ii: it will include 10 asthmatic patients. group iii: it will include 10 copd patients. mir-7, mir-20a, mir-21, mir-22, mir-145 and mir-155 will be measured in serum samples from all subjects

the following will be done for all subjects: 1. thorough history taking with stress on age, age at onset, duration of the disease, smoking history, therapeutic history with stress on their drugs, course of the disease, history of any previous attacks of acute severe asthma or exacerbation of copd. 2. complete physical examination. 3. chest x-ray p.a view. 4. complete blood picture. 5. ventilatory function tests including fvc, fevi and fevi/fvc, pefr and fef25-75% using computerized spirometry apparatus. quantitative assessment of mirna levels: will be used to assay mir-7, mir-20a, mir-21, mir-22, mir-145 and mir-155 in serum samples from all subjects. these mirnas were selected based on prediction algorithms that suggested that these mirnas were involved in the regulation of cytokines.

Eligibility criteria:
inclusion criteria: * group 1: healthy volunteers with no history of chest troubles. * group 2: 10 asthmatic patients with history of paroxysmal wheezing, dyspnea, chest distress, and/or coughing; with reversible airflow limitation as will be measured by an increase in forced expiratory volume in one second (fev1) of at least 12% and of more than 200 ml after inhalation of 200 μg salbutamol. * group 3: 10 copd patients who have chronic airﬂow limitation on spirometry (fev1/fvc is less than 0.7), and the patients have irreversible airflow limitation as will be measured by an increase in (fev1) by less than12% or less than 200 ml after inhalation of 200 μg salbutamol. exclusion criteria: * upper or lower respiratory tract infection during the month preceding the study. * other chronic respiratory or systemic illness. * usage of systemic steroids within 2 months prior to the study. * inability to provide informed consent or who refused to draw off blood.

Keywords: micro rna asthma copd